Foundation Impact Statement - Report - Page 17
Philanthropy & Service
Sigma Kappa has boldly partnered with
the Alzheimer’s Association for over
20 years. Sigma Kappa Foundation’s
current initiative with the Association
is a $1 million grant to support the U.S.
POINTER study. This two-year clinical
trial evaluates whether adopting a healthy lifestyle, delays or prevents the onset of
cognitive decline in high risk individuals. With more than 2,000 volunteers enrolled, the
study is underway. Click here to view the April 2023 Impact Report from the Alzheimer’s
Association to learn more.
Many thanks to our collegiate chapters for their fundraising efforts.
In addition to our continued support of U.S. POINTER, we often hear about
groundbreaking news from the Association. Here is a recent update regarding an FDA
action to grant the first traditional approval of an Alzheimer’s treatment.
During the 2022 walk season, Sigma
Kappas earned the Diamond Level
recognition, once again.
2022-2023 FOUNDATION IMPACT STATEMENT
17